Xolegel (ketoconazole gel) / GSK - LARVOL DELTA

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash (clinicaltrials.gov) - P1 | N=58 | Completed | Sponsor: Mayo Clinic | Active, not recruiting ➔ Completed

Trial completion • Oncology

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash (clinicaltrials.gov) - P1 | N=58 | Active, not recruiting | Sponsor: Mayo Clinic | Trial completion date: Mar 2025 ➔ Sep 2025

Trial completion date • Oncology

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash (clinicaltrials.gov) - P1 | N=58 | Active, not recruiting | Sponsor: Mayo Clinic | N=26 ➔ 58

Enrollment change • Oncology • PLOD2 • SALL4

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases (clinicaltrials.gov) - P1 | N=15 | Terminated | Sponsor: Wake Forest University Health Sciences | Recruiting ➔ Terminated; Low accruals

Surgery • Trial termination • Astrocytoma • Brain Cancer • Breast Cancer • CNS Tumor • Ependymoma • Glioma • Oligodendroglioma • Oncology • Solid Tumor • CD24 • KDR • POU5F1 • VEGFC

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases (clinicaltrials.gov) - P1 | N=19 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial primary completion date: Jul 2024 ➔ Oct 2024

Surgery • Trial primary completion date • Astrocytoma • Brain Cancer • Breast Cancer • CNS Tumor • Ependymoma • Glioma • Oligodendroglioma • Oncology • Solid Tumor • CD24 • KDR • POU5F1 • VEGFC

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash (clinicaltrials.gov) - P1 | N=26 | Active, not recruiting | Sponsor: Mayo Clinic | Trial primary completion date: Jun 2024 ➔ Sep 2024

Trial primary completion date • Oncology • PLOD2 • SALL4

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash (clinicaltrials.gov) - P1 | N=26 | Active, not recruiting | Sponsor: Mayo Clinic | Trial primary completion date: Mar 2024 ➔ Jun 2024

Trial primary completion date • Oncology • PLOD2 • SALL4

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash (clinicaltrials.gov) - P1 | N=26 | Active, not recruiting | Sponsor: Mayo Clinic | Recruiting ➔ Active, not recruiting | N=80 ➔ 26

Enrollment change • Enrollment closed • Oncology • PLOD2 • SALL4

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases (clinicaltrials.gov) - P1 | N=19 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Nov 2023 ➔ Jul 2024 | Trial primary completion date: Oct 2023 ➔ May 2024

Surgery • Trial completion date • Trial primary completion date • Astrocytoma • Brain Cancer • Breast Cancer • CNS Tumor • Ependymoma • Glioma • Oligodendroglioma • Oncology • Solid Tumor • CD24 • KDR • POU5F1 • VEGFC

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases (clinicaltrials.gov) - P1 | N=19 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Aug 2023 ➔ Nov 2023 | Trial primary completion date: Jul 2023 ➔ Oct 2023

Surgery • Trial completion date • Trial primary completion date • Astrocytoma • Brain Cancer • Breast Cancer • CNS Tumor • Ependymoma • Glioma • Oligodendroglioma • Oncology • Solid Tumor • CD24 • KDR • POU5F1 • VEGFC

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Mar 2023 ➔ Mar 2025 | Trial primary completion date: Mar 2023 ➔ Mar 2024

Trial completion date • Trial primary completion date • Oncology

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases (clinicaltrials.gov) - P1 | N=19 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: May 2023 ➔ Aug 2023 | Trial primary completion date: Jan 2023 ➔ May 2023

Surgery • Trial completion date • Trial primary completion date • Astrocytoma • Brain Cancer • Breast Cancer • CNS Tumor • Ependymoma • Glioma • Oligodendroglioma • Oncology • Solid Tumor • CD24 • KDR • POU5F1 • VEGFC

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases (clinicaltrials.gov) - P1 | N=19 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial primary completion date: Sep 2022 ➔ Jan 2023

Trial primary completion date • Astrocytoma • Brain Cancer • Breast Cancer • CNS Tumor • Ependymoma • Glioma • Oligodendroglioma • Oncology • Solid Tumor • CD24 • KDR • POU5F1 • VEGFC

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Mar 2022 ➔ Mar 2023 | Trial primary completion date: Mar 2022 ➔ Mar 2023

Trial completion date • Trial primary completion date • Oncology

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases (clinicaltrials.gov) - P1 | N=19 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial primary completion date: Mar 2022 ➔ Sep 2022

Trial primary completion date • Astrocytoma • Brain Cancer • Breast Cancer • Ependymoma • Glioma • Oligodendroglioma • Oncology • Solid Tumor • CD24 • CD44 • KDR • POU5F1 • VEGFC

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases (clinicaltrials.gov) - P1; N=19; Recruiting; Sponsor: Wake Forest University Health Sciences; Trial primary completion date: Dec 2021 ➔ Mar 2022

Clinical • Trial primary completion date • Astrocytoma • Brain Cancer • Breast Cancer • Ependymoma • Glioma • Oligodendroglioma • Oncology • Solid Tumor • CD24 • CD44 • KDR • POU5F1 • VEGFC

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases (clinicaltrials.gov) - P1; N=19; Recruiting; Sponsor: Wake Forest University Health Sciences; Trial primary completion date: Sep 2021 ➔ Dec 2021

Clinical • Trial primary completion date • Astrocytoma • Brain Cancer • Breast Cancer • Ependymoma • Glioma • Oligodendroglioma • Oncology • Solid Tumor • CD24 • CD44 • KDR • POU5F1 • VEGFC

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases (clinicaltrials.gov) - P1; N=19; Recruiting; Sponsor: Wake Forest University Health Sciences; Trial primary completion date: Apr 2021 ➔ Jul 2021

Clinical • Trial primary completion date • Astrocytoma • Brain Cancer • Breast Cancer • Ependymoma • Glioma • Oligodendroglioma • Oncology • Solid Tumor • CD24 • CD44 • KDR • POU5F1 • VEGFC

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash (clinicaltrials.gov) - P1; N=80; Recruiting; Sponsor: Mayo Clinic; Trial completion date: Mar 2021 ➔ Mar 2022; Trial primary completion date: Mar 2021 ➔ Mar 2022

Clinical • Trial completion date • Trial primary completion date • Dermatology

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases (clinicaltrials.gov) - P1; N=16; Recruiting; Sponsor: Wake Forest University Health Sciences; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases (clinicaltrials.gov) - P1; N=16; Not yet recruiting; Sponsor: Wake Forest University Health Sciences

Clinical • New P1 trial